<DOC>
	<DOCNO>NCT01224782</DOCNO>
	<brief_summary>The aim post-marketing observational study ( PMOS ) evaluate time period need achieve &gt; 30 % decrease intact parathyroid hormone ( iPTH ) compare initial value provide data tolerability compliance treatment Zemplar ( paricalcitol ) capsule therapy secondary hyperparathyroidism ( SHPT ) patient chronic kidney disease ( CKD ) stage 3 4 condition routine clinical practice .</brief_summary>
	<brief_title>Evaluation Treatment With Zemplar Capsules Therapy Secondary Hyperparathyroidism ( SHPT )</brief_title>
	<detailed_description>This non-interventional , observational , open-label , multi-country , multicenter post-marketing study Zemplar ( paricalcitol ) prescribe usual manner accordance term local marketing authorization . Follow visit occur 1 , 3 , 6 , 9 , 12 month screen .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<criteria>Patients 18 year age old Patients chronic kidney disease ( CKD ) stage 3 4 secondary hyperparathyroidism ( SHPT ) Patients Intact Parathyroid Hormone ( iPTH ) &gt; 70 pg/mL chronic kidney disease ( CKD ) stage 3 Intact Parathyroid Hormone ( iPTH ) &gt; 110 pg/mL chronic kidney disease ( CKD ) stage 4 Patients clinically indicated treatment Zemplar capsule Patient must provide authorization use his/her data statistical evaluation enter post marketing observational study ( PMOS ) . Local Law requirement follow Patients clinically important hypercalcemia = Calcium &gt; 2.6 mmol/L ( 10.5 mg/dL ) Patients suffer proved intoxication vitamin D patient know hypersensitivity paricalcitol part product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Zemplar capsule</keyword>
	<keyword>Chronic kidney disease ( CKD ) stage 3 4</keyword>
	<keyword>Secondary hyperparathyroidism ( SHPT )</keyword>
	<keyword>Postmarketing observational study ( PMOS )</keyword>
</DOC>